Maître, Martine https://orcid.org/0009-0001-7928-1014
Baradat, Sophie
Froliger, Mélanie
Turlier, Virginie
Simcic-Mori, Aimée
Gravier, Eléonore
Géniès, Camille
Lauze, Christophe
Huyghe, Céline
Noustens, Anaïs
Alvarez-Georges, Sandrine
Marinescu, Rasvan
Reygagne, Pascal
Bessou-Touya, Sandrine
Mengeaud, Valérie
Duplan, Hélène
Clinical trials referenced in this document:
Documents that mention this clinical trial
Scalp Microbiome Dynamics Can Contribute to the Clinical Effect of a Novel Antiseborrheic Dermatitis Shampoo Containing Patented Antifungal Actives: A Randomized Controlled Study
https://doi.org/10.1007/s13555-025-01408-z
Funding for this research was provided by:
Les Laboratories Pierre Fabre
Article History
Received: 19 February 2025
Accepted: 1 April 2025
First Online: 11 June 2025
Declarations
:
: Martine Maître, Sophie Baradat, Mélanie Froliger, Virginie Turlier, Aimée Simcic-Mori, Eléonore Gravier, Camille Géniès, Christophe Lauze, Céline Huyghe, Anais Noustens, Sandrine Alvarez-Georges, Rasvan Marinescu, Sandrine Bessou-Touya, Valérie Mengeaud, and Hélène Duplan are or were employees of Pierre Fabre Dermo-Cosmétique and Personal Care, France, at the time of the preparation of this manuscript and received salaries, but they do not have any financial interest in the findings described in this manuscript. Pascal Reygagne has previously received honorarium fees Pierre Fabre Dermo-Cosmétique and Personal Care for his role as a speaker, advisory board member, and investigator but did not receive any financial compensation for the performance in this study.
: The study was performed in compliance with the Declaration of Helsinki and its subsequent amendments, as well as good clinical practice guidelines (CHMP/ICH/135/1995 and integrated addendum). It also conformed to Regulation (EC) No. 1223/2009 of the European Commission and the French Decree (no. 2017-884) pertaining to research on cosmetic products. As registration of studies evaluating cosmetic products is not mandatory in the European Union, the study was retrospectively registered under trial number NCT06578962 (28 August 2024) for publication. Prior to enrollment, all subjects provided written informed consent.